Global Times

Inactivate­d vaccines suitable to protect general public

- By GT staff reporters

After the latest coronaviru­s outbreaks, including one in North China’s Hebei Province, prompted the public to discuss whether vaccines can tackle the problem, experts explained although the approved inactivate­d vaccines cannot cure the infected, they are suitable for China to protect the general public.

Hebei, free from the virus for months, reported more than 120 infections as of Wednesday. However, given the nature of the inactivate­d vaccines that have been granted conditiona­l approval, there is little to be gained in using them on confirmed patients or silent carriers, Yang Zhanqiu, a deputy director of the pathogen biology department at Wuhan University, told the Global Times.

An inactivate­d vaccine works by using killed viral particles to expose the body’s immune system to the virus without risking a serious response. “Inactivate­d vaccines function like ‘ building a Great Wall’ to keep the virus out,” Yang said. “This can only prevent infection for healthy people, but it cannot help patients who are already infected, or who are in the incubation period.”

However, for those around the patient who are not yet infected, a vaccinatio­n should be given urgently as a preventive measure, such as to people in Hebei who have not been infected yet, Yang said.

Yang pointed out that another technology route — the new mRNA vaccines — can help infected people battle the virus, or function “inside the Great Wall.” These vaccines carry part of the coronaviru­s’ genetic code into the human body, triggering the body to form viral proteins sufficient to train the immune system to attack the virus, which means that they might ease patients’ condition and reduce damage to the organs.

As few people in China have been infected, the inactivate­d vaccines are suitable and efficient for China’s overall situation.

China is also developing mRNA vaccines and Fosun is cooperatin­g with Pfizer and BioNTech on the route. Fosun launched a phase II clinical trial in November and it showed the vaccine was “90 percent effective.” In December, Fosun said that at least 100 million doses will be provided in China in 2021 when the vaccine is approved.

Inactivate­d vaccines function like ‘ building a Great Wall’ to keep the virus out while mRNA vaccines can help infected people battle the virus, or function “inside the Great Wall.”

Newspapers in English

Newspapers from China